

***In vitro* phase I metabolism of three phenethylamines 25D-NBOMe, 25E-NBOMe and 25N-NBOMe using microsomal and microbial models**

Katharina Elisabeth Grafinger^{1,2}, Katja Stahl³, Andreas Wilke³, Stefan König¹, Wolfgang Weinmann¹

¹ Institute of Forensic Medicine, Forensic Toxicology and Chemistry, University of Bern, Bülhlstrasse 20, 3012 Bern, Switzerland

² Graduate School for Cellular and Biomedical Sciences, University of Bern, Freiestrasse 1, 3012 Bern, Switzerland

³ Department of Mechanical and Process Engineering, University of Applied Sciences Offenburg, Badstrasse 24, 77652 Offenburg, Germany

*corresponding author: Katharina Elisabeth Grafinger, Katharina.grafinger@irm.unibe.ch Institute of Forensic Medicine, Bülhlstrasse 20, 3012 Bern, Switzerland

Metabolism; NBOMe; NPS; pHLM; fungi *Cunninghamella elegans*; metabolism

Abstract:

Numerous 2,5-dimethoxy-*N*-benzylphenethylamines (NBOMe), carrying a variety of lipophilic substituents at the 4-position, are potent agonists at 5-hydroxytryptamine (5HT_{2A}) receptors and show hallucinogenic effects. The present study investigated the metabolism of 25D-NBOMe, 25E-NBOMe and 25N-NBOMe using the microsomal model of pooled human liver microsomes (pHLM) and the microbial model of the fungi *Cunninghamella elegans* (*C. elegans*). Identification of metabolites was performed using liquid chromatography-high resolution-tandem mass spectrometry (LC-HR-MS/MS) with a QqToF instrument. In total, 36 25D-NBOMe phase I metabolites, 26 25E-NBOMe phase I metabolites and 24 25N-NBOMe phase I metabolites were detected and identified in pHLM. Furthermore, 14 metabolites of 25D-NBOMe, eleven 25E-NBOMe metabolites and nine 25N-NBOMe metabolites could be found in *C. elegans*. The main biotransformation steps observed were oxidative deamination, oxidative *N*-dealkylation also in combination with hydroxylation, oxidative *O*-demethylation possibly combined with hydroxylation, oxidation of secondary alcohols, mono- and dihydroxylation, oxidation of primary alcohols and carboxylation of primary alcohols. Additionally, oxidative di-*O*-demethylation for 25E-NBOMe and reduction of the aromatic nitro group and *N*-acetylation of the primary aromatic amine for 25N-NBOMe took place. The resulting 25N-NBOMe metabolites were unique for NBOMe compounds. For all NBOMes investigated, the corresponding 2,5-dimethoxyphenethylamine (2C-X) metabolite was detected. This study reports for the first time 25X-NBOMe *N*-oxide metabolites and hydroxylamine metabolites, which were identified for 25D-NBOMe and 25N-NBOMe and all three investigated NBOMes, respectively. *C. elegans* was capable of generating all main biotransformation steps observed in pHLM and might therefore be an interesting model for further studies of new psychoactive substances (NPS) metabolism.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/dta.2446

1. Introduction:

In the last ten years, new psychoactive substances (NPS) have become a growing problem. Chatwin et al.¹ define NPS as “chemical compounds that have been modified and developed to mimic the effects of drugs which are already prohibited”. Currently, the European Union (EU) Early Warning System, coordinated by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), is monitoring over 620 NPS, with one sixth of them belonging to the chemical class of phenethylamines^{2, 3}. Prominent substances belonging to this class are 2C-type phenethylamines⁴, which are 2,5-dimethoxyphenethylamines, substituted at the 4-position, typically with halogens or alkyl groups, and also 2,5-dimethoxy-*N*-benzylphenethylamines, so called NBOMes which have emerged in recent years⁵. Substitutions on the 4-position include bromine (25B-NBOMe), chlorine (25C-NBOMe), methyl (25D-NBOMe), ethyl (25E-NBOMe), iodine (25I-NBOMe), nitro (25N-NBOMe) groups but the unsubstituted form (25H-NBOMe) is also available⁶, which has been detected as an impurity in blotter papers⁷. These substances were found to be potent 5HT_{2A} receptor agonists⁸⁻¹¹. Furthermore, Braden et al. could show that the addition of the *N*-methoxybenzyl group to 2C-X compounds significantly increases their affinity to the 5-HT_{2A} receptor and therefore results in higher behavioural responses¹². NBOMes and their homologues produce psycho- and cardiovascular stimulant effects in addition to hallucinations¹³. In cases of acute drug intoxication, sympathomimetic toxicity such as tachycardia, hypertension, mydriasis, agitation, vasoconstriction and hyperthermia were observed¹⁴⁻¹⁷, which could point towards serotonin syndrome. Recommended treatment in case of intoxication is heart rate, blood pressure and body temperature monitoring¹⁸. Furthermore, for acute treatment of sympathomimetic toxidrome, administration of benzodiazepines, fluid replacement and physical cooling should be performed to control agitation, cardiovascular stimulation and hyperthermia due to serotonin toxicity^{16, 18, 19}. NBOMe compounds are usually taken in doses of 200 µg to 2000 µg (depending on the compound), mainly by sublingual application on blotter papers, and they have been reported to be sold as counterfeit LSD products^{20, 21}. Several NBOMe case studies of intoxication with non-fatal^{15, 16, 22} and fatal intoxication^{13, 23, 24} have been reported. The presence of metabolites is proof of consumption of the parent substrate. Therefore, metabolism studies are needed to identify metabolites of NPS, which can then be used as biomarkers to confirm consumption. Another issue concerning NPS is the lack of reference standards, which can be overcome by identifying unique fingerprints of drug metabolites.

In order to form phase I and phase II metabolites, different *in vivo* and *in vitro* models are available. Human studies are ethically not favourable and therefore animal *in vivo* studies or *in vitro* alternatives are commonly used. Pooled human liver microsomes (pHLM) have been shown to be a reliable *in vitro* model for the generation of phase I metabolites²⁵⁻²⁷. An alternative to *in vitro* models, such as primary human hepatocytes (PHH), pooled human S9 fraction (pS9) or pHLM²⁸, are microbial models of the fungus *Cunninghamella elegans* (*C. elegans*). Microbial models have the advantage of low cost, easy handling, scale-up capability and further to reduce use of animals²⁹. Moreover, *C. elegans* has the enzymatic activity of both phase I and II enzymes²⁹ and holds the cytochrome P450 CYP509A1 enzyme³⁰. This class of fungi has the ability to facilitate reactions such as hydroxylation, carboxylation, dihydrodiol formation, oxidative defluorination, *N*-dealkylation, glucuronidation and sulfation^{31, 32}, as well as those catalysed by human CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4^{29, 32-34}. It was recently shown by Nielsen et al.³⁵ that the main enzymes involved in the 25I-NBOMe metabolism are CYP3A4 and CYP2D6. Caspar et al.⁴ reported that for 25B-NBOMe and 25C-NBOMe the enzymes CYP1A2, CYP3A4, CYP2C9 and CYP2C19 play a crucial role.

The aim of the present study was to conduct metabolism studies of three different NBOMe analogues, 25D-NBOMe, 25E-NBOMe and 25N-NBOMe employing pHLM and *C. elegans* and to identify phase I metabolites based on mass spectrometric data. Besides the most common analogues 25B-NBOMe and 25I-NBOMe, the three analogues have previously been identified on confiscated blotter papers ⁷. All measurements were performed using liquid chromatography-high resolution-tandem mass spectrometry (LC-HR-MS/MS) and metabolites were identified according to their precursor masses, the most abundant product ions and the isotope patterns. So far no biotransformation data are available on the three investigated NBOMes.

2. Materials and Methods

2.1 Chemicals and Reagents

Yeast extract, malt extract and peptone from soy beans were obtained from Carl Roth (Karlsruhe, Germany), glucose from Applichem (Darmstadt, Germany). *C. elegans* strain DMSZ 1908 was obtained from Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). Sodium hydroxide, magnesium chloride and disodiumhydrogenphosphate-dihydrate were purchased from Merck AG (Zug, Switzerland), sulfosalicylic acid and superoxide dismutase (6016 units/mg protein) from Sigma Aldrich (Buchs, Switzerland). Pooled human S9 fraction (pS9) (150 donors, 20 mg/mL), pooled human liver microsomes (pHLM) (150 donors, 20 mg/mL), NADPH-regenerating solutions A/B, UGT-reaction mix A/B and 0.5 M potassium phosphate buffer pH 7.4 were obtained from Corning (New York, NY, USA). Hydrochloride salts of 25D-NBOMe (98.5 %), 25E-NBOMe (>98.5 %), and 25N-NBOMe (98.5 %), were purchased from Lipomed (Arllesheim, Switzerland). The reference standard of 25B-NBOMe-D₃ (0.01 mg/mL in methanol) was obtained from Cerilliant (Round Rock, TX, USA). Formic acid (analytical grade, 98 %) and ammonium formate were obtained from Fluka (Sigma-Aldrich, Buchs, Switzerland), methanol (absolute, HPLC grade) from Biosolve (Chemie Brunschwig, Basel, Switzerland), acetonitrile (HPLC gradient grade, 99.9 %) and 1-chlorobutane (HPLC gradient grade, 99.8 %) from Acros Organics (Chemie Brunschwig, Basel, Switzerland). Direct-Q water purification system from Millipore (Zug, Switzerland) was used to produce in-house ultrapure water. All solutions and samples were handled using precision pipettes from Gilson (Mettmenstetten, Switzerland) and Socorex Isba S.A (Ecublens, Switzerland)

2.2 *In Silico* predictions

Prediction of possible metabolites was carried out in order to assist in the interpretation of the collected mass spectrometric data, using Meteor Nexus v.3.0.1 (Lhasa Limited). It is a knowledge-based expert system that predicts the biotransformation of a substrate ³⁶. Parameters were as follows: species human, processing direction breath first, maximal depth 3, absolute reasoning: minimum likelihood equivocal and relative reasoning: level of cut-off 2. Results of the *in silico* predictions were compared to information independent LC-HR-MS/MS measurements using the Analyst software 1.6 TF with MasterView™ Software Version 1.1 with the extracted ion current (XIC) tool.

2.3 Microsomal assay using pHLM

For generating phase I metabolites, microsomal *in vitro* experiments were performed as previously published ²⁷. Briefly, the following components were mixed in a reaction tube, with a final volume of

50 µL and indicated concentrations are final concentrations: deionized water, potassium phosphate buffer (100 mM), magnesium chloride (5 mM), superoxide dismutase (200 units/mL), NADPH-regenerating solution A (NADP⁺ and glucose-6-phosphate) and B (glucose-6-phosphate dehydrogenase), pHLM (1 mg/mL) and a reference standard of one of the three investigated NBOMes (25 µM). Samples were incubated for 60 min at 37 °C, which is a commonly reported incubation time in literature. Simultaneously, blanks containing no drug substrates and negative controls containing no pHLM were prepared. The reactions were stopped by adding 50 µL ice cold acetonitrile containing an internal standard of 25B-NBOMe-D₃. After mixing, the samples were centrifuged at 17' 000 g and 8 °C for 10 min and the supernatants transferred to autosampler vials. The samples were evaporated to dryness at 50 °C under nitrogen and reconstituted in 50 µL water/acetonitrile/formic acid, (95:5:0.1; v/v/v). Experiments were conducted in triplicates.

2.4 Microbial assay using fungi *C. elegans*

The growth medium was prepared according to the DSMZ Medium 186 (Leibniz Institute DSMZ - German Collection of Microorganisms and Cell Cultures)³⁷. The media components containing yeast extract (3 g/L), malt extract (3 g/L) and peptone from soy beans (5 g/L) (solution A, without agar) and glucose (10 g/L) (solution B) were dissolved separately in deionized water. After autoclaving both solutions were mixed. For the cultivation of *C. elegans*, the medium (30 mL) was inoculated with a piece of mycelium from the agar plate. The culture flasks were shaken for three days at 100 rpm at 28 °C on a rotary shaker (KS 260 basic, IKA-Werke GmbH & Co. Kg, Staufen im Breisgau, Germany). On day three, the *C. elegans* biomasses were transferred to new flasks containing fresh medium and were again inoculated with a piece of mycelium. This way, two different growth stadiums of the fungi biomasses were obtained, which increased the ability of the fungi to metabolise. Solutions of each NBOMe were prepared in 70 % ethanol with concentrations of 50 µM. On day four, 800 µL of NBOMe solution was added to the culture flask and incubated for 72 hours by shaking at 100 rpm at 28 °C. In preliminary experiments, the incubation time was evaluated for time points 24, 48, 72 and 96 hours. Results showed that 72 and 96 hours of incubation resulted equally in the most amount of metabolites, therefore 72 hours were chosen as incubation time. After three days, the reaction was stopped and the growth medium and the fungi biomass stored separately in 30 mL falcon tubes at -20 °C, this stops the fungi's ability to further metabolise. Samples were stored at -20 °C until they were processed. Experiments were carried out in duplicates. In preliminary experiments, the growth medium has been analysed but only the parent compounds were detected. The reason for this is that the fungi only takes up the substrates in the growth medium but does not release the formed metabolites back to it. Therefore, for the detection and identification of metabolites in the fungi biomass was intensively analysed. Additionally, this made it necessary to homogenize the fungi biomass.

Extractions were performed as follows: on average, 1.10 g (range 1.03-1.15 g) fungi biomass were weighed into a homogenization tube (gentleMacs M Tubes, Macs Miltenyi Biotec, Bergisch Gladbach, Germany), and 4 mL of phosphate puffer pH 9 added. The fungi sample was homogenized with a gentle Macs Dissociator, using a pre-programmed gradient of 45 seconds. One mL of the fungi solution was then transferred to a new vial and 10 µL internal standard 25B-NBOMe-D₃ (2000 ng/mL) and 1.5 mL 1-chlorobutane added. Afterwards, the sample was mixed for at least 10 min followed by centrifugation for 10 min at 17' 000 g rpm at 8 °C. The supernatant was then transferred to an

autosampler vial and evaporated under nitrogen at 50 °C. Finally, the sample was reconstituted in 100 µL water/acetonitrile/formic acid (95:5:0.1; v/v/v).

2.5 LC-HR-MS/MS analysis

All samples were analysed using a Dionex Ultimate 3000 HPLC system (Thermo Fisher Scientific, Reinach, Switzerland) coupled to a 5600 TripleToF System equipped with a DuoSpray interface and Analyst software 1.6 TF with MasterView™ Software Version 1.1 (Sciex, Toronto, Canada). For data evaluation, the following parameters were chosen: a cut-off mass error of 5 ppm, intensities higher than 500 cps and only peaks eluting in the gradient within 2 and 22 min. Chromatographic separation was performed on a reversed phase Kinetex C8 column, 2.6 µm, 100 Å, 100 x 2.1 mm (Phenomenex, Basel, Switzerland). The mobile phase consisted of water with 0.1 % formic acid (A) and acetonitrile with 0.1 % formic acid (B) with a flow rate of 0.25 mL/min. The following gradient was applied: 0-1 min: 2.5 % B, 1-20 min: 2.5 % to 40 % B, 20-24 min: 40-97.5 % B, 24-28 min: 97.5 % B, 28-30 min: 97.5 -2.5 % B and 30-35 min: 2.5 % B. The injection volume was 1.0 µL. The MS parameters were as follows: ESI voltage 5.0 kV, source temperature 650 °C, curtain gas 55 arbitrary units, gas 1 and 2 at 55 arbitrary units. All data were acquired in positive ion mode. Information dependent data acquisition (IDA) was carried out using a survey scan from m/z 100 to 950, triggering the acquisition of product ion mass spectra for the nine most abundant precursor ions in a mass range from m/z 50 to 950. For dependent and survey scans the accumulation time was set to 40 ms and 50 ms, respectively. The collision energy was set to 35 eV and a collision energy spread of \pm 15 eV. The SCIEX QqToF system used is automatically calibrated at the start of every new chromatogram by injection of a calibration solution directly in the ion source (post-column).

3. Results and Discussion

In order to exclude matrix peaks as potential metabolites, all data obtained were compared to blank pHLM and fungi samples, containing the matrix but no drug and negative control samples containing no pHLM, respectively. The *in silico* predictions obtained from Meteor Nexus v.3.0.1 software assisted in the analysis of obtained IDA LC-HR-MS/MS scans. Extracted ion chromatograms of each 25X-NBOMe and their metabolites are presented in Figures 1 to 3, with the upper chromatogram (A) belonging to the pHLM sample and the lower one (B) to the fungi *C. elegans* sample. The proposed biotransformation pathways for each compound are displayed in Figure 4 to 6. Metabolites labelled with (F) were present in both pHLM and *C. elegans*. Detailed lists of all identified metabolites are displayed in Tables 1 to 3.

3.1 Identification of metabolites

The molecular structure of 25X-NBOMe compounds and metabolites can be divided into two parts: the 4-substituted 2,5-dimethoxyphenethylamine is referred as the 2C part and the *N*-(2-methoxybenzyl) is the so called NBOMe part⁴. Figure 7 presents the nomenclature used for the description of fragmentation and positions of metabolisation. A large number of metabolites was identified for each 25X-NBOMe and therefore only the characteristic product ions used for identification will be discussed in detail. Representative product ion mass spectra of metabolites for each 25X-NBOMe are displayed in Figure 8. All other mass spectra can be found in the supporting information. The parent compounds and their metabolites were identified by precursor ion masses of the respective protonated molecule, their most abundant product ions and isotope pattern, and

for those metabolites occurring in both pHLM and the fungi *C. elegans*, by their retention times. The protonated masses and product ions given are the calculated values.

For the 25X-NBOMe parent compounds, the respective precursor ions and the product ions with m/z 121.0653 and m/z 91.5048 (representing the NBOMe part) were present. The product ions resulted due to amine cleavage of the NBOMe moiety forming $[C_8H_9O]^+$ (m/z 121.0653) and further demethoxylation via neutral loss of formaldehyde forming the tropylium ion $[C_7H_7]^+$ (m/z 91.0548)³⁸. These product ions were consistent with previously published data on 25B-NBOMe, 25C-NBOMe and 25I-NBOMe, because the alterations between the 25X-NBOMe are on the 2C part at the 4-position^{4, 6, 39}. The following observations can be made for all metabolites of 25X-NBOMe substances: If product ions with m/z 121.0653 and m/z 91.0534 are present, no biotransformation occurs at the NBOMe part. A product ion with m/z 107.0497 is characteristic for oxidative *O*-demethylation at the 2-position at the NBOMe part forming an hydroxy-cycloheptatrienylium ($[C_7H_7O]^+$). A product ion with m/z 123.0446 ($[C_7H_7O_2]^+$) indicates that simultaneous oxidative *O*-demethylation and hydroxylation occurred on the NBOMe part. Hydroxylation on the NBOMe ring led to the product ions with m/z 137.0603 ($[C_8H_9O_2]^+$) in combination with a product ion with either m/z 107.0497 ($[C_7H_7O]^+$) or m/z 123.0446 ($[C_7H_7O_2]^+$). Dihydroxylation at the NBOMe part resulted in a product ion with m/z 153.0552 ($[C_8H_9O_3]^+$). All other product ions were specific to the 2C part and are discussed in the following paragraphs.

3.1.1 25D-NBOMe

Thirty-six distinctive 25D-NBOMe metabolites were identified in pHLM and 14 in fungi *C. elegans*. The fragmentation of the parent compound 25D-NBOMe ($C_{19}H_{25}NO_3$ precursor ion $[M+H]^+$ m/z 316.1907) resulted in product ions with m/z 179.1072, m/z 121.0653, m/z 91.0538 and the protonated molecule with m/z 316.1900. This product ion represented amine cleavage forming $[C_{11}H_{15}O_2]^+$, and the last two are specific for the intact NBOMe part. These product ions can be used among others for identifying metabolites in combination with previously mentioned product ions. When a product ion with m/z 179.1072 ($[C_{11}H_{15}O_2]^+$) was present no biotransformation took place on the 2C part but was possible on the amine. An intact 2,5-dimethoxy-1,4-dimethyl cation was identified with a product ion with m/z 165.0916 ($[C_{10}H_{13}O_2]^+$). The three *O*-demethylated metabolites (D7-D9: $C_{18}H_{23}NO_3$ precursor ion $[M+H]^+$ m/z 302.1751) were differentiated depending on following product ions (besides the precursor ions and product ions): the occurrence of the product ions m/z 121.0653 and m/z 91.0548 characteristic for the NBOMe part means that *O*-demethylation occurs on the 2C part, and a product ion of m/z 107.0497 ($[C_7H_7O]^+$) means that *O*-demethylation takes place on the NBOMe moiety. The mono-hydroxylated in combination with *O*-demethylated metabolites (D10-D19: $C_{18}H_{23}NO_4$ precursor ion $[M+H]^+$ m/z 318.1700) were identified as follows: The mass spectrum of metabolite D10 only displays two product ions which are typical for an intact NBOMe part. Therefore, the only statement that can be made is that both *O*-demethylation and hydroxylation occur on the 2C part. Due to the lack of fragmentation and since tertiary hydrocarbons are preferred over secondary hydrocarbons as site of hydroxylation, it is more likely that hydroxylation occurs on the 2,5-dimethoxy-4-dimethyl⁴⁰. The fragmentation of D11 displays the loss of a water molecule from the precursor ion forming m/z 300.1600 ($[C_{18}H_{22}NO_3]^+$), which correlates with a rearrangement forming a double bond. Furthermore, the two characteristic NBOMe part product ions are present, which indicate that biotransformation must have occurred on the 2C part. For metabolite D12, the position of hydroxylation was narrowed down to α position or the amine

forming a hydroxylamine because the product ion of m/z 151.0759 ($[C_9H_{11}O_2]^+$) correlates with an α -cleavage. The metabolite D14 has a very interesting combination of product ions, which would singularly point into other directions but in their combination only one structure is possible. The typical NBOMe part product ions are not present, which means that either *O*-demethylation or hydroxylation occurred on this part. Both, *O*-demethylation and hydroxylation on the NBOMe part is not possible because then a product ion with m/z 123.0446 ($[C_7H_7O_2]^+$) would be observed. The product ion with m/z 137.0603 ($[C_8H_9O_2]^+$) in combination with m/z 165.0916 ($[C_{10}H_{13}O_2]^+$) result from *O*-demethylation on the 2C part and are formed due to β -cleavage and amine cleavage, respectively. The product ion of m/z 107.0497 ($[C_7H_7O]^+$) is formed by α' -cleavage of the NBOMe part. For metabolite D15, the site of hydroxylation could only be narrowed down to α or β position. As described for D14, the product ion with m/z 123.0446 ($[C_7H_7O_2]^+$) can only occur when *O*-demethylation and hydroxylation are occurring combined on the NBOMe part. The product ion with m/z 179.1072 ($[C_{11}H_{15}O_2]^+$) results from amine cleavage and occurs from an intact 2C part. The hydroxylation is narrowed down to vicinal position. For the identification of the site of mono-hydroxylation, several specific product ions were used (D21-D25: $C_{19}H_{25}NO_4$ precursor ion $[M+H]^+$ m/z 332.1856). Firstly, an intact 2,5-dimethoxy-4-methylphenyl moiety (therefore hydroxylation not taking place on this site) correlated with a product ion with m/z 180.1025 ($[C_{10}H_{14}NO_2]^+$). Secondly, hydroxylation occurring on the 2C part resulted in a product ion with m/z 210.1130 ($[C_{11}H_{16}NO_3]^+$), which could be further narrowed down with a product ion with m/z 195.1010 ($[C_{11}H_{15}O_3]^+$), which in turn specified that hydroxylation took place on the 2C part but not on the amine. The exact site of hydroxylation is discussed more in detail as follows: For D22, the product ion with m/z 165.0916 ($[C_{10}H_{13}O_2]^+$) is formed due to α -cleavage, the product ion m/z 195.1021 ($[C_{11}H_{15}O_3]^+$) is formed due to amine cleavage. On the basis of these two fragments and the typical NBOMe part fragment the site of hydroxylation can only be the α position. D23 and D25 have the same mass spectra. The two product ions with m/z 195.1021 ($[C_{11}H_{15}O_3]^+$), m/z 180.1025 ($[C_{10}H_{14}NO_2]^+$) and the two NBOMe part ions are formed due to α -cleavage and amine cleavage, respectively. Based on these two fragments, it can be concluded that hydroxylation occurs in α or β position. For metabolite D24, the position of the hydroxylation can be narrowed down to the vicinal position due to following fragments: The presence of the product ions with m/z 179.1072 ($[C_{11}H_{15}O_2]^+$) means that no biotransformation occurs on the 2C part, it is formed due to amine cleavage. The absence of the typical NBOMe part product ions let conclude that hydroxylation must occur on this part. And finally, the product ions with m/z 137.0603 ($[C_8H_8O_2]^+$) and m/z 107.0497 ($[C_7H_7O]^+$) narrow down the site of hydroxylation to vicinal position because they are formed by dealkylation and α' -cleavage, respectively. The *N*-oxide metabolite D27 is eluting 0.91 min after the parent substrate, which is typical for *N*-oxides on reversed phase columns⁴¹, and the product ions of m/z 179.1072 ($[C_{11}H_{15}O_2]^+$) (formed by amine cleavage) and the two NBOMe ions lead to the only conclusion, that it is an *N*-oxide. D29 is identified as follows: the product ion with m/z 151.0759 ($[C_9H_{11}O_2]^+$) correlates with an intact 2,5-dimethoxy-4-methylphenyl moiety and is formed by β -cleavage. Using the two product ions with m/z 195.1021 ($[C_{11}H_{15}O_3]^+$) and m/z 135.0446 ($[C_8H_7O_2]^+$) (formed by amine cleavage and dealkylation), the sites of hydroxylation and oxidation of alcohols can be narrowed down to α - and vicinal position. The fragmentation of D30 resulted in m/z 165.0916 ($[C_{10}H_{13}O_2]^+$), m/z 137.0603 ($[C_8H_8O_2]^+$) and m/z 107.0497 ($[C_7H_7O]^+$), resulting from α -cleavage, dealkylation and α' -cleavage, respectively. Using these product ions the sites of hydroxylation are α and vicinal position. Metabolites D35 and D36 have identical mass spectra. Using the product ions m/z 179.1072 ($[C_{11}H_{15}O_2]^+$) and m/z 153.0552 ($[C_8H_9O_3]^+$), which are formed by amine cleavage and dealkylation, it can be concluded that both

hydroxylations must occur on the NBOMe part. Furthermore, the product ion m/z 123.0446 ($[C_7H_7O_2]^+$), formed by α' -cleavage, determines that one hydroxylation takes place in vicinal position and the other one on the NBOMe ring.

3.1.2 25E-NBOMe

For 25E-NBOMe, 26 distinctive metabolites were identified in pHLM and 11 in the fungi *C. elegans*. The fragmentation of 25E-NBOMe (precursor ion $[M+H]^+$ m/z 329.1991) resulted in product ions with m/z 193.1222, m/z 121.0653 and m/z 91.0534. These product ions correlated with amine cleavage of the 2C part forming $[C_{12}H_{17}O_2]^+$, and further the two specific NBOMe part product ions. Again, this first product ion with m/z 193.1229 ($[C_{12}H_{17}O_2]^+$) represented an intact 2C part (independent of biotransformation on the amine). When hydroxylation took place on the 2C part a product ion with m/z 209.1178 ($[C_{12}H_{17}O_3]^+$) was observed. When a product ion with m/z 181.0865 ($[C_{10}H_{13}O_3]^+$) was found, simultaneous double oxidative *O*-demethylation and hydroxylation on the 2C part occurred. For the two identified di-*O*-demethylated metabolites E5 and E6 ($C_{18}H_{23}NO_3$, precursor ion $[M+H]^+$ m/z 302.1751), three different sites of *O*-demethylation are possible. This could be narrowed down by the presence (E6) or absence (E5) of the two typical NBOMe part product ions m/z 121.0653 and m/z 91.0534 or the product ion m/z 107.0497 ($[C_7H_7O]^+$) that correlates with *O*-demethylation occurring on the NBOMe part. The mono-*O*-demethylation can occur on three different sites (E7-E9: $C_{19}H_{25}NO_3$, precursor ion $[M+H]^+$ m/z 316.1907). E7 and E8 had the same mass spectra, with the product ions m/z 179.1072 ($[C_{11}H_{15}O_2]^+$), m/z 121.0653 and m/z 91.0534. These correlate with amine cleavage and the two typical NBOMe part fragments, respectively. E9 fragmented among others into the product ions m/z 107.0497 ($[C_7H_7O]^+$), which stands for *O*-demethylation occurring on the NBOMe part and m/z 193.1229 ($[C_{12}H_{17}O_2]^+$) representing an intact 2C part. Metabolites E10 and E11 with di-*O*-demethylation and simultaneous hydroxylation ($C_{18}H_{23}NO_4$ precursor ion $[M+H]^+$ m/z 318.1700) displayed similar fragmentation with the product ions m/z 181.0865 ($[C_{10}H_{13}O_3]^+$) and m/z 121.0653 and m/z 91.0534, correlating with amine cleavage and the NBOMe part product ions. Hence, both di-*O*-demethylation and hydroxylation must occur on the 2C part. Eight different mono-*O*-demethylated and hydroxylated metabolites were detected (E12-E19: $C_{19}H_{25}NO_4$, precursor ion $[M+H]^+$ m/z 332.1856). For metabolite E18 no mass spectrum was triggered, therefore no statement on its structure can be made. The sites of *O*-demethylation and hydroxylation were differentiated as follows: E14 and E19 display the same product ions with m/z 179.1072 ($[C_{11}H_{15}O_2]^+$), m/z 165.0916 ($[C_{10}H_{13}O_2]^+$), m/z 121.0653 and m/z 91.0534, which are formed by amine cleavage, α -cleavage and the two typical NBOMe part fragments, respectively. Due to these product ions hydroxylation can only occur on the amine forming hydroxylamine metabolites. The mass spectra of E15 and E16 have identical predominant product ions with m/z 137.0603 ($[C_8H_9O_2]^+$) and m/z 107.0497 ($[C_7H_7O]^+$), which correlate with mono-hydroxylation on the NBOMe ring and *O*-demethylation on the 2C ring. The main product ions used for the identification of the structure of metabolite E17 are m/z 193.1229 ($[C_{12}H_{17}O_2]^+$) and 123.0446 ($[C_7H_7O_2]^+$), which are formed by amine cleavage and dealkylation respectively. The five different mono-hydroxylated metabolites (E21-E25: $C_{20}H_{27}NO_4$ precursor ion $[M+H]^+$ m/z 346.2013) were identified as follows: For metabolites E21 and E22 the same structure was identified. The mass spectra of E21 and E22 display the product ions m/z 209.1178 ($[C_{12}H_{17}O_3]^+$), m/z 179.1072 ($[C_{11}H_{15}O_2]^+$), and the two specific NBOMe part ions m/z 121.0653 and m/z 91.0534. The hydroxylation takes place at α -position due to the following observations: the product ion with m/z

209.1178 correlates with the hydroxylation on the 2C part and is formed by amine cleavage; the product ion of m/z 179.1072 can only occur when the hydroxylation does not take place on the 4-ethyl-1-methyl-2,5-dimethoxyphenyl and is formed by α -cleavage. The mass spectrum obtained for E23 leads us to the conclusion that the hydroxylation must occur on the 2C part. E24 fragmentation resulted in product ions of m/z 193.1229 ($[C_{12}H_{17}O_2]^+$), m/z 137.0603 ($[C_8H_9O_2]^+$) and m/z 107.0497 ($[C_7H_7O]^+$), correlating with dealkylation and α' -cleavage. The combination of these product ions unambiguously identifies the vicinal position as site of hydroxylation.

3.1.3 25N-NBOMe

25N-NBOMe transformation resulted in the fewest number of metabolites: 24 in total in pHLM and 9 in fungi *C. elegans*. The mass spectrum of 25N-NBOMe (precursor ion $[M+H]^+$ m/z 347.1601) shows the molecular ion and the product ions with m/z 121.0653 and m/z 91.0534. When a product ion with m/z 210.0766 ($[C_{10}H_{12}NO_4]^+$) was present, no biotransformation took place on the 2C part. Oxidative *O*-demethylation on the 2C part resulted in a product ion with m/z 196.0610 ($[C_9H_{10}NO_4]^+$). The metabolite resulting from the reduction of the aromatic nitro group (N8 precursor ion $[M+H]^+$ m/z 317.1860) fragmented into m/z 180.1014 ($[C_{10}H_{14}NO_2]^+$), m/z 165.0781 ($[C_9H_{11}NO_2]^+$), m/z 121.0653 and m/z 91.0534 due to cleavage of the amine, α -cleavage and the two product ions representing the intact NBOMe part. The site of *O*-demethylation occurring for metabolites N6 and N7 ($C_{17}H_{22}N_2O_3$ precursor ion $[M+H]^+$ m/z 303.1703) was differentiated by the presence of the product ions m/z 166.0868 ($[C_9H_{12}NO_2]^+$), m/z 121.0653 and m/z 91.0534, with the first one being formed by amine cleavage and the two characteristic ions for NBOMe part fragments and denote *O*-demethylation on the 2C part (N7). Opposed to this, the occurrence of the product ion m/z 180.1025 ($[C_{10}H_{14}NO_2]^+$) (also occurring for N8), which correlates with an intact 4-ethyl-2,5-dimethoxyaniline, implying *O*-demethylation taking place on the NBOMe part (N6). For metabolites N9-N11 ($C_{16}H_{18}N_2O_5$ precursor ion $[M+H]^+$ m/z 319.1288) the sites of di-*O*-demethylation were also differentiated by the presence (N9) or absence (N10, N11) of the NBOMe part product ions. Additionally, the mass spectra of N10 and N11 displayed the product ions m/z 196.0610 ($[C_9H_{10}NO_4]^+$) and m/z 107.497 ($[C_7H_7O]^+$), correlating with amine cleavage and dealkylation, and can both only occur if *O*-demethylation occurs simultaneously on the 2C and NBOMe part. Nevertheless, the site of *O*-demethylation on the 2C part could not be determined. Accordingly, metabolites N12, N13 and N14 ($C_{17}H_{20}N_2O_5$ precursor ion $[M+H]^+$ m/z 333.1445) were identified, with the mass spectra of N12 and N13 displaying the two NBOMe part product ions, and hence, *O*-demethylation occurring on the 2C part and the product ions m/z 210.0766 ($[C_{10}H_{12}NO_4]^+$) and m/z 107.497 ($[C_7H_7O]^+$), which can only occur if the 2C part is intact and *O*-demethylation taking place on the NBOMe part, respectively. The *O*-demethylated and hydroxylated metabolites (N15-N18: $C_{17}H_{20}N_2O_6$ precursor ion $[M+H]^+$ m/z 349.1394) were identified by using mainly the NBOMe part fragments and the product ions m/z 137.0603 ($[C_8H_9O_2]^+$), m/z 123.0446 ($[C_7H_7O_2]^+$), the exact site of hydroxylation was determined as follows: The predominant product ions in the mass spectrum of N15 m/z 210.0766 ($[C_{10}H_{12}NO_4]^+$) and m/z 123.0446 ($[C_7H_7O_2]^+$), are formed by amine cleavage and dealkylation. It can be concluded that the 2C part is intact and that both *O*-demethylation and hydroxylation must occur on the NBOMe part. The mass spectrum of N16 resulted in very little fragmentation with the precursor ion m/z 349.1394 and two product ions m/z 121.0653 and m/z 91.0534. Therefore, it was only possible to conclude the site of *O*-demethylation to be on the 2C part. Due to the absence of further product ions it is more likely that the hydroxylation also occurs on the 2,5-dimethoxy-4-

nitrophenyl. For N17 the fragmentation was similar, with the precursor ion and two product ions m/z 137.0603 ($[C_8H_9O_2]^+$) and m/z 123.0446 ($[C_7H_7O_2]^+$). Hence, *O*-demethylation must occur on the NBOMe part. The site of hydroxylation could only be narrowed down to the NBOMe part. Due to the absence of product ions formed by α and β cleavage it is more likely that the hydroxylation occurs on the 2,5-dimethoxy-4-nitrophenyl. The mass spectrum of N18 was a bit more complicated to interpret. N18 fragmented into the following product ions m/z 227.1026 ($[C_{10}H_{15}N_2O_4]^+$), m/z 210.0766 ($[C_{10}H_{12}N_2O_4]^+$), m/z 195.0532 ($[C_9H_9NO_4]^+$), m/z 137.0603 ($[C_8H_9O_2]^+$) and m/z 123.0446. These are formed by dealkylation, amine cleavage, a further loss of a methyl radical and dealkylation, respectively⁴². Hence both *O*-demethylation and hydroxylation must occur on the 2C part. The fragmentation of N19 ($C_{20}H_{26}N_2O_4$ precursor ion $[M+H]^+$ m/z 359.1965) displayed the following product ions: m/z 237.1239 ($[C_{12}H_{17}N_2O_3]^+$), m/z 222.1130 ($[C_{12}H_{16}NO_3]^+$), m/z 121.0653 and m/z 91.0534, which are formed by dealkylation and amine cleavage, respectively. The mass spectrum of N20 ($C_{18}H_{20}N_2O_6$ precursor ion $[M+H]^+$ m/z 359.1965) showed very little fragmentation with the two NBOMe part ions and product ion m/z 239.0668 ($[C_{10}H_{11}N_2O_5]^+$), the latter being formed by dealkylation. Therefore, the oxidation of secondary alcohols can only occur on α - or β -position. The identification of the structures of the mono-hydroxylated metabolites N21- N24 ($C_{18}H_{22}N_2O_6$ precursor ion $[M+H]^+$ m/z 363.1551) is more complicated due to little fragmentation. Metabolite N21 fragmented into the two NBOMe part product ions and therefore the hydroxylation must occur on the 2C part. It is eluting 1.66 min after the parent substrate and is consequently identified as an *N*-oxide metabolite. *N*-oxides typically elute after the parent substrate on a reverse phase column^{27, 41}. The fragmentation of N22 displayed the product ions m/z 345.1450 ($[C_{18}H_{21}N_2O_5]^+$), m/z 121.0653 and m/z 91.0534. The first one is formed by cleavage of the hydroxyl on the amine and the rearrangement forming a double bond. Therefore N22 was identified to be a hydroxylamine metabolite. The position of hydroxylation of N23 and N24 was identified to be 5 position on the NBOMe part ring using the product ions m/z 137.0603 ($[C_8H_9O_2]^+$), m/z 109.0645 ($[C_6H_5O_2]^+$), and m/z 107.0485 correlating with dealkylation, simultaneous cleavage of the NBOMe ring and the methyl on the methoxy group forming a protonated quinone.

3.2 Microsomal biotransformation

Incubation of pHLM with 25D-NBOMe, 25E-NBOMe and 25N-NBOMe resulted in 36, 26 and 24 metabolites, respectively. Several different biotransformational mechanisms were observed in all three 25X-NBOMe compounds. Hydroxylation of the parent substrate (+15.995 Da) formed six 25D-NBOMe metabolites (D21-D26), five 25E-NBOMe metabolites (E21-E25) and three 25N-NBOMe metabolites (N22-N24). Hydroxylation of the parent compound was observed at α -position for D22, E21 and E22, β - or α -position for D23, D25 and α -position or on the amine for D26, E23, E25 and N22. D23, D25 and N22 were further metabolised by oxidation of the secondary alcohol forming D20 and N20. For both D24 and E24 hydroxylation was identified to be on the vicinal position. Two *N*-oxide metabolites were observed (D27/ N21) both eluting after the parent substrates, which is typical for *N*-oxides on reversed phase columns^{27, 41}. The resulting mono-hydroxylated metabolites underwent further oxidative *O*-demethylation (D10-D19/ E12-E19/ N15-N18; mass difference to parent substrate -14.0157 Da) on the 2C part (D10-D12, D14, D15, D17, D19/ E12-E16, E19/ N16) or on the NBOMe part (D16/ E17 / N15, N17, N18). Oxidative *O*-demethylation of the parent compound (mass difference to parent -14.0156 Da) on either the 2nd or 5th position of the 2C part or 2nd position on the NBOMe part was observed for all three compounds resulting in three metabolites (D7/ E8/

N12; D8/ E7/ N13; D9/ E9/ N14;). Further oxidative *O*-demethylation (mass difference to parent substrate -28.0312 Da) of these metabolites resulted in metabolites found for all three tested 25X-NBOMes (D4/ E6/ N9; D5/ E5/ N10; D6/ N11;). Only for E6 further metabolism occurred, forming a di-*O*-demethylated and hydroxylated metabolite E10 and E11. For all three substrates, the respective 2,5-dimethoxyphenethylamine (2C-X) metabolites could be identified (D2, E3, N3) formed by oxidative *N*-dealkylation (-120.0575 Da). 2C-X are also biologically active compounds used for recreational purposes and have been previously identified as 25B-NOMe and 25I-NBOMe metabolites⁴. This 2C-X metabolite was further metabolised by oxidative deamination forming 2-methoxybenzoic acid (D1/ E1/ N1; precursor ion $[M+H]^+$ m/z 153.0546), identical for all three substrates. For 25E-NBOMe and 25N-NBOMe E3 and N3 were further metabolised by oxidative *O*-demethylation to E2 and N2 (precursor ion $[M+H]^+$ m/z 196.1332 and m/z 213.0870). The 25D-NBOMe and 25E-NBOMe 2C-X metabolites were hydroxylated forming D3 and E4. For metabolites D27 (precursor ion $[M+H]^+$ m/z 346.1649) and E26 (precursor ion $[M+H]^+$ m/z 360.1806) carboxylation of the primary alcohol or alkyl was observed, respectively.

Biotransformation of 25E-NBOMe and 25D-NBOMe was very similar. However, 25D-NBOMe produced seven additional dihydroxylated metabolites (D30-36, precursor ion $[M+H]^+$ m/z 348.1806), which could neither be found for 25E-NBOMe nor for 25N-NBOMe. Sites of dihydroxylation were for D30 in α and vicinal position, for which in vicinal position oxidation of a primary alcohol took place. Metabolites D31 and D32 had the hydroxylations taking place on the 2C ring and in α -position (D32) or β -position (D31). Whereas for D33 it could be undoubtedly determined that a hydroxylamine was formed and a second hydroxylation took place in α -position. Metabolites D35 and D36 had hydroxylation occurring on the NBOMe ring and in vicinal position. Unique 25N-NBOMe metabolites were formed due to reduction of the aromatic nitro group at the 4-position (N8, precursor ion $[M+H]^+$ m/z 317.1860), which was further metabolised by oxidative *O*-demethylation (N6, N7, precursor ion $[M+H]^+$ m/z 303.1703), or *N*-acetylation of the primary aromatic amine (N19, precursor ion $[M+H]^+$ m/z 359.1965).

In summary, the observed biotransformation pathways of 25D-NBOMe were oxidative *O*-deamination, oxidative *N*-dealkylation also in combination with hydroxylation, oxidative *O*-demethylation possibly combined with hydroxylation, oxidation of secondary alcohols, mono- and dihydroxylation, oxidation of primary alcohols and carboxylation of primary alcohols. For 25E-NBOMe the same metabolism steps were observed differing in the sites of metabolic modifications. Additionally, oxidative di-*O*-demethylation was seen. 25N-NBOMe metabolism was very similar to 25D-NBOMe and 25E-NBOMe, with mostly the same steps observed. In addition, due to the presence of the aromatic nitro group, the following mechanisms were observed: reduction of the aromatic nitro group, also in combination with demethylation and *N*-acetylation of the primary aromatic amine.

Meteor Nexus was a helpful aid in the evaluation of obtained IDA-LC-HR-MS/MS data in combination with the MasterView™ software. Nevertheless, a critical interpretation of data is necessary using described parameters. Every hit passing this criterion must then be manually checked if the peak was a peak or simply noise and if the isotopic ratio was correct. The mass spectra are then used to unambiguously identify a metabolite. Only 19 metabolites were not predicted by Meteor Nexus but identified by the authors using the gained knowledge about typical fragmentation patterns.

Therefore, the in silico predictions provided by Meteor Nexus are a valuable tool for data evaluation but nevertheless need to be assessed critically.

Caspar et al.⁴ reported 35 phase I metabolites of 25B-NBOMe of which 13 followed the same biotransformation pathways as 35 metabolites of the 90 metabolites found for 25D-NBOMe, 25E-NBOMe and 25N-NBOMe. *N*-oxides and hydroxylamines of 25X-NBOMes were identified in the present study, which have not yet been reported in literature.

3.3 Microbial biotransformation

Microbial experiments incubations of 25D-NBOMe, 25E-NBOMe or 25N-NBOMe with *C. elegans* generated 14, 11 and 9 metabolites, respectively. Each metabolite found in fungi was also identified in pHLM. Metabolites were identified according to their precursor ion, fragmentation, isotope ratios and retention times, which were the same as for the metabolites found in previous experiments with pHLM. Biotransformation steps observed in fungi *C. elegans* were oxidative *N*-dealkylation, oxidative *O*-demethylation also in combination with hydroxylation, oxidation of secondary alcohols and mono- and di-hydroxylation for all three compounds, and for 25N-NBOMe additionally reduction of the aromatic nitro groups and *N*-hydroxylation of secondary aliphatic amines. For 25D-NBOMe and 25N-NBOMe also *N*-oxide formation and hydroxylamine metabolites were identified.

The microsomal method of pHLM generated three times more metabolites than the microbial method of the fungi *C. elegans*. Watanabe et al.³² reported to have found more metabolites of JWH-018 and other similar synthetic cannabinoids, in *C. elegans* than literature data reports found in pHLM. But Watanabe et al. used a different *C. elegans* line, which could explain different results. The ability of the fungi *C. elegans* to metabolise xenobiotics and especially NPS could depend on the chemical class of the drug. Therefore, it is advised to conduct more metabolism studies with *C. elegans*, investigating different chemical classes of NPS, in order to be able to conclude the fungi's ability to be a good metabolism model.

4 Conclusion

Microsomal and microbial experiments resulted in thirty-six 25D-NBOMe phase I metabolites, twenty-six 25E-NBOMe phase I metabolites and twenty-four 25N-NBOMe phase I metabolites. One metabolite identical for all three compounds was found (E1/ D1/ N1). For the first time, an *N*-oxide 25X-NBOMe metabolite was identified, namely D27 and N21, which eluted 0.91 min and 1.66 min after the parent substrate, respectively. Additionally, hydroxylamine metabolites were identified due to their fragmentation (D11, D12, D17, D26, D33; E12, E13, E14, E19, E23, E25; N22). For 25N-NBOMe unique metabolites were detected due to the reduction of the aromatic nitro group. Main biotransformation steps observed were oxidative *O*-demethylation, mono and dihydroxylation, *N*-oxide formation, hydroxylamine formation and *N*-dealkylation. Additionally, metabolites found in both pHLM and fungi *C. elegans* were eluting at the same retention times and could therefore be identified according their retention times. The fungi *C. elegans* could generate all main phase I biotransformation steps observed for all three compounds and therefore is an interesting model for further studies of NPS metabolism. Nevertheless, in the current study no phase II metabolites were identified in the fungi *C. elegans* samples. When authentic biological samples of consumers of 25D-NBOMe, 25E-NBOMe or 25N-NBOMe are available, these metabolites can be used for target analysis, and might confirm the predictions from in-vitro experiments to some extent. Additionally,

phase II metabolites (e.g. glucuronides) might be present in urine samples, which might have similar mass spectrometric product ions.

5 Acknowledgments

The authors would like to thank Yannik Winter and Patricia Wybraniec for assisting with the fungi experiments, and Dr. Susanne Nussbaumer, Achim Caspar and Dr. Patrick Juchli for fruitful discussions. Additionally, the authors would like to thank Dr. Daniel Pasin for thorough proof reading of the manuscript for language mistakes and Prof. W.M.A. Niessen for his help with the interpretation of metabolite N18.

6 Funding

This research received financial support by the Swiss Federal Office of Public Health (BAG project Nr. 15.029013).

7 Conflict of Interest

The authors declare no conflict of interest.

8 References

- 1 Chatwin C. Assessing the 'added value' of European policy on new psychoactive substances. *Int J Drug Policy* 2017; 40:111-116. DOI: 10.1016/j.drugpo.2016.11.002.
- 2 EMCDDA. European Drug Report 2017: Trends and Developments. Publications Office of the European Union, Luxembourg., doi:10.2810/610791, 2017
- 3 (EDND) TEisadond. *The European information system and database on new drugs (EDND)*. [webpage] 2018; 07.02.2018 [cited 2018 15.02.2018].
- 4 Caspar AT, Brandt SD, Stoever AE, Meyer MR, Maurer HH. Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human and rat urine by GC-MS, LC-MSn, and LC-HR-MS/MS approaches. *J Pharm Biomed Anal* 2017; 134:158-169. DOI: 10.1016/j.jpba.2016.11.040.
- 5 Suzuki J, Dekker MA, Valenti ES, et al. Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature. *Psychosomatics* 2015; 56(2):129-39. DOI: 10.1016/j.psym.2014.11.002.
- 6 Boumrah Y, Humbert L, Phanithavong M, Khimeche K, Dahmani A, Allorge D. In vitro characterization of potential CYP- and UGT-derived metabolites of the psychoactive drug 25B-NBOMe using LC-high resolution MS. *Drug Test Anal* 2016; 8(2):248-56. DOI: 10.1002/dta.1865.
- 7 Poklis JL, Raso SA, Alford KN, Poklis A, Peace MR. Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and other dimethoxyphenyl-N-[(2-Methoxyphenyl) methyl]ethanamine derivatives on blotter paper. *J Anal Toxicol* 2015; 39(8):617-23. DOI: 10.1093/jat/bkv073.
- 8 Heim R. Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur Entwicklung eines neuen Struktur-Wirkungskonzepts. , in *Fachbereich Biologie, Chemie, Pharmazie*2003; Freie Universität Berlin: Berlin, Germany.333.
- 9 Hansen M. Design and synthesis of selective serotonin receptor agonists for positron emission tomography imaging of the brain, in *Faculty of Pharmaceutical Sciences*2010; University of Copenhagen: Copenhagen, Denmark.227.

- 10 Glennon RA, Dukat M, el-Bermawy M, et al. Influence of amine substituents on 5-HT_{2A} versus 5-HT_{2C} binding of phenylalkyl- and indolylalkylamines. *J Med Chem* 1994; 37(13):1929-35.
- 11 Nichols DE, Sassano MF, Halberstadt AL, et al. N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT₂ Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues. *ACS Chem Neurosci* 2015; 6(7):1165-75. DOI: 10.1021/cn500292d.
- 12 Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT_{2A} receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. *Mol Pharmacol* 2006; 70(6):1956-64. DOI: 10.1124/mol.106.028720.
- 13 Lowe LM, Peterson BL, Couper FJ. A case review of the first analytically confirmed 25I-NBOMe-related death in Washington State. *J Anal Toxicol* 2015; 39(8):668-71. DOI: 10.1093/jat/bkv092.
- 14 Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). *Neuropharmacology* 2015; 99:546-53. DOI: 10.1016/j.neuropharm.2015.08.034.
- 15 Hill SL, Doris T, Gurung S, et al. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. *Clin Toxicol (Phila)* 2013; 51(6):487-92. DOI: 10.3109/15563650.2013.802795.
- 16 Hermanns-Clausen M, Angerer V, Kithinji J, Grumann C, Auwarter V. Bad trip due to 25I-NBOMe: a case report from the EU project SPICE II plus. *Clin Toxicol (Phila)* 2017. DOI: 10.1080/15563650.2017.1319572:1-3. DOI: 10.1080/15563650.2017.1319572.
- 17 Bersani FS, Corazza O, Albano G, et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. *Biomed Res Int* 2014; 2014:734749. DOI: 10.1155/2014/734749.
- 18 Liechti M. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. *Swiss Med Wkly* 2015; 145:w14043. DOI: 10.4414/smw.2015.14043.
- 19 Tang MH, Ching CK, Tsui MS, Chu FK, Mak TW. Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. *Clin Toxicol (Phila)* 2014; 52(5):561-5. DOI: 10.3109/15563650.2014.909932.
- 20 Duffau B, Camargo C, Kogan M, Fuentes E, Cassels BK. Analysis of 25 C NBOMe in seized blotters by HPTLC and GC-MS. *J Chromatogr Sci* 2016; 54(7):1153-8. DOI: 10.1093/chromsci/bmw095.
- 21 Zuba D, Sekula K, Buczek A. 25C-NBOMe--new potent hallucinogenic substance identified on the drug market. *Forensic Sci Int* 2013; 227(1-3):7-14. DOI: 10.1016/j.forsciint.2012.08.027.
- 22 Rajotte JW, Palmentier JFP, Wallage HR. Drug recognition evaluation and chemical confirmation of a 25C-NBOMe-impaired driver. *J Forensic Sci* 2017; 62(5):1410-1413. DOI: 10.1111/1556-4029.13433.
- 23 Laskowski LK, Elbakoush F, Calvo J, et al. Evolution of the NBOMes: 25C- and 25B- sold as 25I-NBOMe. *J Med Toxicol* 2015; 11(2):237-41. DOI: 10.1007/s13181-014-0445-9.
- 24 Gee P, Schep LJ, Jensen BP, Moore G, Barrington S. Case series: toxicity from 25B-NBOMe--a cluster of N-bomb cases. *Clin Toxicol (Phila)* 2016; 54(2):141-6. DOI: 10.3109/15563650.2015.1115056.
- 25 Franz F, Angerer V, Moosmann B, Auwarter V. Phase I metabolism of the highly potent synthetic cannabinoid MDMB-CHMICA and detection in human urine samples. *Drug Test Anal* 2017; 9(5):744-753. DOI: 10.1002/dta.2049.
- 26 Franz F, Angerer V, Brandt SD, et al. In vitro metabolism of the synthetic cannabinoid 3,5-AB-CHMFUPPYCA and its 5,3-regioisomer and investigation of their thermal stability. *Drug Test Anal* 2017; 9(2):311-316. DOI: 10.1002/dta.1950.

- 27 Grafinger KE, Hadener M, König S, Weinmann W. Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples. *Drug Test Anal* 2017. 10.1002/dta.2245. DOI: 10.1002/dta.2245.
- 28 Richter LHJ, Flockerzi V, Maurer HH, Meyer MR. Pooled human liver preparations, HepaRG, or HepG2 cell lines for metabolism studies of new psychoactive substances? A study using MDMA, MDDP, butylone, MDPPP, MDPV, MDPB, 5-MAPB, and 5-API as examples. *J Pharm Biomed Anal* 2017; 143:32-42. DOI: 10.1016/j.jpba.2017.05.028.
- 29 Zhang D, Yang Y, Leakey JE, Cerniglia CE. Phase I and phase II enzymes produced by *Cunninghamella elegans* for the metabolism of xenobiotics. *FEMS Microbiol Lett* 1996; 138(2-3):221-6.
- 30 Wang RF, Cao WW, Khan AA, Cerniglia CE. Cloning, sequencing, and expression in *Escherichia coli* of a cytochrome P450 gene from *Cunninghamella elegans*. *FEMS Microbiol Lett* 2000; 188(1):55-61.
- 31 Asha S, Vidyavathi M. *Cunninghamella*--a microbial model for drug metabolism studies--a review. *Biotechnol Adv* 2009; 27(1):16-29. DOI: 10.1016/j.biotechadv.2008.07.005.
- 32 Watanabe S, Kuzhiumparambil U, Winiarski Z, Fu S. Biotransformation of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by *Cunninghamella elegans*. *Forensic Sci Int* 2016; 261:33-42. DOI: 10.1016/j.forsciint.2015.12.023.
- 33 Watanabe S, Kuzhiumparambil U, Nguyen MA, Cameron J, Fu S. Metabolic profile of synthetic cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by *Cunninghamella elegans*. *AAPS J* 2017; 19(4):1148-1162. DOI: 10.1208/s12248-017-0078-4.
- 34 Dube AK, Kumar MS. Biotransformation of bromhexine by *Cunninghamella elegans*, *C. echinulata* and *C. blakesleeana*. *Braz J Microbiol* 2017; 48(2):259-267. DOI: 10.1016/j.bjm.2016.11.003.
- 35 Nielsen LM, Holm NB, Leth-Petersen S, Kristensen JL, Olsen L, Linnet K. Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH. *Drug Test Anal* 2017; 9(5):671-679. DOI: 10.1002/dta.2031.
- 36 Marchant CA, Briggs KA, Long A. In silico tools for sharing data and knowledge on toxicity and metabolism: derek for windows, meteor, and vitic. *Toxicol Mech Methods* 2008; 18(2-3):177-87. DOI: 10.1080/15376510701857320.
- 37 Leibniz-Institute-DMSZ. 186. UNIVERSAL MEDIUM FOR YEASTS (YM). 2007; [cited 2018 06.03.2018]; Available from: https://www.dsmz.de/microorganisms/medium/pdf/DSMZ_Medium186.pdf.
- 38 Pasin D, Cawley A, Bidny S, Fu S. Characterization of hallucinogenic phenethylamines using high-resolution mass spectrometry for non-targeted screening purposes. *Drug Test Anal* 2017; 9(10):1620-1629. DOI: 10.1002/dta.2171.
- 39 Leth-Petersen S, Gabel-Jensen C, Gillings N, et al. Metabolic Fate of Hallucinogenic NBOMes. *Chem Res Toxicol* 2016; 29(1):96-100. DOI: 10.1021/acs.chemrestox.5b00450.
- 40 Bonse G, Metzler M. Biotransformationen organischer Fremdstoffen, Stuttgart, Germany: Georg Thime Verlag. 1181978.
- 41 Michely JA, Helfer AG, Brandt SD, Meyer MR, Maurer HH. Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS. *Anal Bioanal Chem* 2015; 407(25):7831-42. DOI: 10.1007/s00216-015-8955-0.
- 42 Niessen WM, Correa RA. Interpretation of MS-MS mass spectra of drugs and pesticides Wiley Series on Mass Spectrometry, ed. D.M. Desiderio and J.A. Loo. 10.1002/9781119294269, Hoboken, USA: John Wiley & Sons, Inc 2017.

Table 1 Identified metabolites of 25D-NBOMe in pHLM and Fungi *C. elegans* sorted by their protonated mass [M+H]⁺. The three most abundant product ions of 25D-NBOMe and its metabolites are listed with their relative intensities (percentage of the base peak intensity) as indices numbers.

Name	Biotransformation	Formula	[M+H] ⁺ []	pHLM			Fungi <i>C. elegans</i>			Product ions [m/z] and ion ratios [%]
				error [ppm]	RT [min]	Intensity [cps]	error [ppm]	RT [min]	Intensity [cps]	
D1	Oxidative deamination	C ₈ H ₈ O ₃	153.0546	-0.5	9.91	10'193				135.0437 ₁₀₀ 92.0247 ₂₃ 77.0380 ₇₅
D2	Oxidative <i>N</i> - dealkylation	C ₁₁ H ₁₇ NO ₂	196.1332	-0.7	9.86	97'100	-0.8	9.87	7'216	179.1063 ₁₀₀ 164.0832 ₉₅ 149.0587 ₇₀
D3	Oxidative <i>N</i> - dealkylation, Hydroxylation	C ₁₁ H ₁₇ NO ₃	212.1281	0.5	5.42	8'273				195.1012 ₁₀₀ 180.0775 ₆₅ 135.0805 ₉₂
D4	Oxidative <i>O</i> - didemethylation	C ₁₇ H ₂₁ NO ₃	288.1594	0	10.54	4'848				172.8598 ₁₂ 121.0641 ₁₀₀ 91.0536 ₂₃
D5	Oxidative <i>O</i> - didemethylation	C ₁₇ H ₂₁ NO ₃	288.1594	0.8	12.66	2'841				165.0901 ₁₀₀ 150.0685 ₃₀ 107.0460 ₅₀
D6	Oxidative <i>O</i> - didemethylation	C ₁₇ H ₂₁ NO ₃	288.1594	0.3	13.04	13'336				271.1325 ₆₁ 137.0584 ₁₀₀ 121.0643 ₆₀
D7	Oxidative <i>O</i> - demethylation	C ₁₈ H ₂₃ NO ₃	302.1751	0.6	14.35	524'928	-0.1	14.38	3'936	165.0900 ₆ 121.0640 ₁₀₀ 91.0535 ₂₃
D8	Oxidative <i>O</i> - demethylation	C ₁₈ H ₂₃ NO ₃	302.1751	-0.1	14.53	269'321	0.8	14.57	9'485	121.0645 ₁₀₀ 93.0706 ₈ 91.0542 ₃₅
D9	Oxidative <i>O</i> - demethylation	C ₁₈ H ₂₃ NO ₃	302.1751	0.3	15.48	161'255	0.0	15.53	21'765	179.1068 ₁₀₀ 164.0831 ₄₀ 107.0489 ₃₀

25D-NBOMe		C₁₉H₂₅NO₃	316.1907	0	17.38	7'095'732	0.7	17.36	12'608'060	179.1081₁₉ 121.0644₁₀₀ 91.0532₃₈
D10	Oxidative O-demethylation, Hydroxylation	C ₁₈ H ₂₃ NO ₄	318.1700	0.3	10.06	4'892	2	10.05	378	121.0644 ₁₀₀ 93.0702 ₁₂ 91.0533 ₃₀
D11	Oxidative O-demethylation, Hydroxylation	C ₁₈ H ₂₃ NO ₄	318.1700	-0.3	10.26	5'155				300.1581 ₂₄ 121.0639 ₁₀₀ 91.0535 ₃₀
D12	Oxidative O-demethylation, Hydroxylation	C ₁₈ H ₂₃ NO ₄	318.1700	0.2	10.79	15'336				151.0745 ₁₅ 121.0640 ₁₀₀ 91.0535 ₂₄
D13	Oxidative O-demethylation, Hydroxylation	C ₁₈ H ₂₃ NO ₄	318.1700	-1	10.81	12'705				No MS2 triggered
D14	Oxidative O-demethylation, Hydroxylation	C ₁₈ H ₂₃ NO ₄	318.1700	-0.5	12.28	4'640				165.0880 ₁₅ 137.0587 ₁₀₀ 107.481 ₂₈
D15	Oxidative O-demethylation, Hydroxylation	C ₁₈ H ₂₃ NO ₄	318.1700	0.9	12.60	3'415				181.0819 ₃₇ 137.0597 ₁₀₀ 121.0645 ₈₂
D16	Oxidative O-demethylation, Hydroxylation	C ₁₈ H ₂₃ NO ₄	318.1700	0.3	13.01	26'168				179.1065 ₁₀₀ 164.0826 ₃₉ 123.0433 ₄₂
D17	Oxidative O-demethylation, Hydroxylation	C ₁₈ H ₂₃ NO ₄	318.1700	-0.9	13.38	17'803				300.1578 ₃₃ 121.0642 ₁₀₀ 91.0534 ₃₅
D18	Oxidative O-demethylation, Hydroxylation	C ₁₈ H ₂₃ NO ₄	318.1700	-1.5	13.53	1'190				No MS2 triggered
D19	Oxidative O-demethylation, Hydroxylation	C ₁₈ H ₂₃ NO ₄	318.1700	-0.2	15.07	1'461				121.0636 ₁₀₀ 91.0547 ₃₀ 93.0705 ₂₀

D20	Oxidation of Secondary Alcohols	$C_{19}H_{23}NO_4$	330.1700	0.2	14.8	20'507	-0.2	14.86	591	121.0640 ₁₀₀ 98.9835 ₈ 91.0531 ₂₅
D21	Mono-hydroxylation	$C_{19}H_{25}NO_4$	332.1856	0.5	12.03	6'869	2.5	12.02	1'262	300.1607 ₂₁ 121.0640 ₁₀₀ 91.0535 ₂₈
D22	Mono-hydroxylation	$C_{19}H_{25}NO_4$	332.1856	-0.4	12.46	981'889	-0.5	12.52	34'466	165.0903 ₃₀ 121.0641 ₁₀₀ 91.0536 ₃₀
D23	Mono-hydroxylation	$C_{19}H_{25}NO_4$	332.1856	-0.1	14.89	26'440	2.5	14.98	817	195.1010 ₂₅ 121.0639 ₁₀₀ 91.0531 ₂₃
D24	Mono-hydroxylation	$C_{19}H_{25}NO_4$	332.1856	0.9	15.28	467'705	-0.1	15.29	7'258	179.1063 ₁₅ 137.0595 ₁₀₀ 107.0487 ₂₀
D25	Mono-hydroxylation	$C_{19}H_{25}NO_4$	332.1856	0.9	15.6	27'674	0.5	15.66	376	195.1010 ₅₀ 121.0642 ₁₀₀ 91.0541 ₂₃
D26	Mono-hydroxylation	$C_{19}H_{25}NO_4$	332.1856	0.6	16.04	61'417	1.0	16.09	38'829	314.1753 ₄₀ 121.0640 ₁₀₀ 91.0538 ₁₈
D27	N-oxide formation	$C_{19}H_{25}NO_4$	332.1856	0.6	18.29	8'220	0.6	18.31	2'860	179.1074 ₃₅ 121.0640 ₁₀₀ 91.0538 ₂₈
D28	Carboxylation of Primary Alcohol	$C_{19}H_{23}NO_5$	346.1649	-0.6	12.40	37'481				121.0639 ₁₀₀ 93.0686 ₁₀ 91.0535 ₂₀
D29	Oxidation of Primary Alcohols	$C_{19}H_{23}NO_5$	346.1649	0.7	16.6	10'705				195.1015 ₁₀₀ 180.0773 ₃₈ 135.0802 ₂₈
D30	dihydroxylation	$C_{19}H_{25}NO_5$	348.1806	-0.1	10.70	42'259				165.0906 ₂₁ 137.0594 ₁₀₀ 107.0476 ₂₆

D31	Dihydroxylation	C ₁₉ H ₂₅ NO ₅	348.1806	0.8	11.36	5'865				330.1699 ₃₁ 121.0640 ₁₀₀ 91.0533 ₂₀
D32	Dihydroxylation	C ₁₉ H ₂₅ NO ₅	348.1806	0.6	11.59	1'516				181.0835 ₁₅ 121.0638 ₁₀₀ 91.0543 ₂₀
D33	Dihydroxylation	C ₁₉ H ₂₅ NO ₅	348.1806	0.3	13.41	4'722	-0.4	13.52	984	165.0907 ₄₅ 121.0640 ₁₀₀ 91.0534 ₂₀
D34	Dihydroxylation	C ₁₉ H ₂₅ NO ₅	348.1806	1	13.85	3'409				No MS2 triggered
D35	Dihydroxylation	C ₁₉ H ₂₅ NO ₅	348.1806	-0.9	14.00	7'535				193.1339 ₃₅ 179.1067 ₁₀₀ 153.0549 ₇₅
D36	Dihydroxylation	C ₁₉ H ₂₅ NO ₅	348.1806	0.4	15.10	4'807				196.1310 ₄₄ 179.1054 ₁₀₀ 153.0539 ₇₀

Table 2 Identified metabolites of 25E-NBOMe identified in pHLM and fungi *C. elegans* sorted by their protonated mass [M+H]⁺.

Name	Biotransformation	Sum formula	[M+H] ⁺ [m/z]	pHLM			Fungi <i>C. elegans</i>			Product ions [m/z] and ion ratios [%]
				error [ppm]	RT [min]	Intensity [cps]	error [ppm]	RT [min]	Intensity [cps]	
E1	Oxidative deamination	C ₈ H ₈ O ₃	153.0546	-0.8	9.95	11'370				135.0429 ₁₀₀ 92.0242 ₂₆ 77.0373 ₇₅
E2	Oxidative <i>N</i> - dealkylation	C ₁₁ H ₁₇ NO ₂	196.1332	-2.4	9.13	2'789				179.1054 ₁₀₀ 164.0820 ₃₈ 113.9388 ₃₂
E3	Oxidative <i>N</i> - dealkylation	C ₁₂ H ₁₉ NO ₂	210.1489	-0.2	12.42	202'532	-0.4	12.42	11'062	193.1209 ₈₆ 178.0977 ₁₀₀ 163.0744 ₆₈
E4	Oxidative <i>N</i> - dealkylation, Hydroxylation	C ₁₂ H ₁₉ NO ₃	226.1438	0.6	7.12	36'736				209.1164 ₉₇ 194.0933 ₅₂ 151.0739 ₁₀₀
E5	Oxidative di- <i>O</i> - demethylation	C ₁₈ H ₂₃ NO ₃	302.1751	0.5	14.74	4'614				196.1311 ₂₀ 179.1058 ₁₀₀ 107.0484 ₄₀
E6	Oxidative di- <i>O</i> - demethylation	C ₁₈ H ₂₃ NO ₃	302.1751	0.4	14.88	8'145				285.1449 ₁₀₀ 151.0733 ₉₈ 121.0625 ₈₀
E7	Oxidative <i>O</i> - demethylation	C ₁₉ H ₂₅ NO ₃	316.1907	-0.1	16.23	248'424	-0.7	16.26	7'191	179.1064 ₁₀ 121.0645 ₁₀₀ 91.0534 ₂₅
E8	Oxidative <i>O</i> - demethylation	C ₁₉ H ₂₅ NO ₃	316.1907	0.8	16.50	248'524	0.8	16.54	7'219	179.1602 ₄ 121.0644 ₁₀₀ 91.0537 ₂₈
E9	Oxidative <i>O</i> - demethylation	C ₁₉ H ₂₅ NO ₃	316.1907	-0.3	17.52	155'849	-0.5	17.52	73'875	193.1226 ₁₀₀ 178.0990 ₃₅ 107.0490 ₂₇

E10	Oxidative di-O-demethylation, Hydroxylation	C ₁₈ H ₂₃ NO ₄	318.1700	-0.8	12.60	2'806				181.0861 ₃₁ 121.0638 ₁₀₀ 91.0531 ₂₉
E11	Oxidative di-O-demethylation, Hydroxylation	C ₁₈ H ₂₃ NO ₄	318.1700	0.4	12.37	7'251				181.0838 ₃₅ 121.0639 ₁₀₀ 91.0530 ₃₀
25E-NBOMe		C₂₀H₂₇NO₃	330.2064	0.7	19.32	5'315'492	0.2	19.33	10'145'481	193.1222₂₇ 121.0644₁₀₀ 91.0534₂₁
E12	Oxidative O-demethylation, Hydroxylation	C ₁₉ H ₂₅ NO ₄	332.1856	-0.2	11.74	3'469				314.1756 ₂₆ 121.0642 ₁₀₀ 91.0528 ₃₅
E13	Oxidative O-demethylation, Hydroxylation	C ₁₉ H ₂₅ NO ₄	332.1856	0.3	12.05	16'104	1.8	12.05	1'744	314.1713 ₈ 121.0636 ₁₀₀ 91.0530 ₂₃
E14	Oxidative O-demethylation, Hydroxylation	C ₁₉ H ₂₅ NO ₄	332.1856	0.5	12.36	26'801	0.5	12.38	4'448	179.1049 ₂₇ 165.0909 ₃₅ 121.0636 ₁₀₀
E15	Oxidative O-demethylation, Hydroxylation	C ₁₉ H ₂₅ NO ₄	332.1856	-0.9	14.15	3'579				137.0592 ₁₀₀ 107.0488 ₃₂ 98.9824 ₂₃
E16	Oxidative O-demethylation, Hydroxylation	C ₁₉ H ₂₅ NO ₄	332.1856	-0.3	14.58	12'378				314.1574 ₅ 137.0588 ₁₀₀ 107.0484 ₂₅
E17	Oxidative O-demethylation, Hydroxylation	C ₁₉ H ₂₅ NO ₄	332.1856	-0.5	15.14	27'927				193.1223 ₁₀₀ 178.0982 ₄₀ 123.0437 ₃₅
E18	Oxidative O-demethylation, Hydroxylation	C ₁₉ H ₂₅ NO ₄	332.1856	0.8	15.25	9'900				No MS2 triggered
E19	Oxidative O-demethylation, Hydroxylation	C ₁₉ H ₂₅ NO ₄	332.1856	0.4	16.91	1'259				179.1082 ₂₂ 121.0642 ₁₀₀ 98.9825 ₃₀

E20	Oxidation of alkyl chain	$C_{20}H_{25}NO_4$	344.1856	-0.4	15.41	184'684	-0.4	15.45	3'561	121.0641 ₁₀₀ 93.0690 ₆ 91.0534 ₂₀
E21	Mono-hydroxylation	$C_{20}H_{27}NO_4$	346.2013	-0.7	13.45	101'785	0.2	13.47	14'303	179.1065 ₃₂ 121.0642 ₁₀₀ 91.0532 ₂₁
E22	Mono-hydroxylation	$C_{20}H_{27}NO_4$	346.2013	1	13.85	1'556'125	-0.4	13.87	186'454	179.1065 ₃₂ 121.0642 ₁₀₀ 91.0532 ₂₃
E23	Mono-hydroxylation	$C_{20}H_{27}NO_4$	346.2013	-0.9	16.77	12'437				209.1166 ₃₂ 121.0641 ₁₀₀ 91.0533 ₂₀
E24	Mono-Hydroxylation	$C_{20}H_{27}NO_4$	346.2013	0.4	17.23	410'802	-0.7	17.25	23'002	193.1226 ₂₀ 137.0595 ₁₀₀ 107.0485 ₂₀
E25	Mono-hydroxylation	$C_{20}H_{27}NO_4$	346.2013	0	17.98	52'036	-0.8	18.02	30'785	328.1906 ₄₀ 121.0640 ₁₀₀ 91.0535 ₂₀
E26	Carboxylation of alkyl	$C_{20}H_{25}NO_5$	360.1806	0.9	18.20	25'554				209.1145 ₇₀ 194.0937 ₄₀ 191.1050 ₁₀₀

Table 3 Metabolites of 25N-NBOMe identified in pHLM and fungi *C. elegans* samples sorted by the mass of the protonated molecule [M+H]⁺.

Name	Biotransformation	Formula	[M+H] ⁺ [m/z]	pHLM			Fungi <i>C. elegans</i>			Product ions [m/z] and ion ratios [%]
				error [ppm]	RT [min]	Intensity [cps]	error [ppm]	RT [min]	Intensity [cps]	
N1	Oxidative deamination	C ₈ H ₈ O ₃	153.0546	0.4	9.92	18'644				135.0434 ₁₀₀ 92.0242 ₂₇ 77.0383 ₆₀
N2	Oxidative <i>O</i> - demethylation	C ₉ H ₁₂ N ₂ O ₄	213.0870	0.9	4.94	4'512				196.0611 ₁₀₀ 151.0385 ₅₅ 137.0596 ₉₈
N3	Oxidative <i>N</i> - dealkylation	C ₁₀ H ₁₄ N ₂ O ₄	227.1026	1	7.85	161'465	-0.4	7.81	9'373	210.0758 ₁₀₀ 195.0519 ₃₃ 151.0748 ₆₁ 210.0772 ₆₃ 151.0742 ₈₅ 125.0462 ₁₀₀
N4	Oxidative deamination	C ₁₀ H ₁₃ NO ₅	228.0866	0.9	14.28	97'337				196.0607 ₁₀₀ 141.9586 ₅₅ 137.0589 ₃₀
N5	Oxidative deamination	C ₁₀ H ₁₁ NO ₆	242.0659	-1	14.01	3'383				180.1003 ₁₀₀ 165.0743 ₁₉ 150.0535 ₁₃
N6	Oxidative <i>O</i> - demethylation	C ₁₇ H ₂₂ N ₂ O ₃	303.1703	-0.7	13.85	1'451				166.0858 ₁₀₀ 121.0643 ₇₀ 91.0532 ₃₃
N7	Oxidative <i>O</i> - demethylation	C ₁₇ H ₂₂ N ₂ O ₃	303.1703	0.6	7.04	4'846				180.1014 ₁₀₀ 165.0781 ₁₃ 121.0646 ₂₈
N8	Reduction of Aromatic Nitro Groups	C ₁₈ H ₂₄ N ₂ O ₃	317.1860	0.6	9.4	53'684	0.5	9.38	67'350	121.0640 ₁₀₀ 93.0693 ₇ 91.0538 ₂₃
N9	Oxidative di- <i>O</i> - demethylation	C ₁₆ H ₁₈ N ₂ O ₅	319.1288	-1	12.69	7'906				213.0686 ₇₅
N10	Oxidative di- <i>O</i> -	C ₁₆ H ₁₈ N ₂ O ₅	319.1288	-0.6	13.00	4'555				

	demethylation									196.0603 ₈₂
										107.0483 ₁₀₀
N11	Oxidative di- <i>O</i> -demethylation	C ₁₆ H ₁₈ N ₂ O ₅	319.1288	-0.3	11.59	7'303				213.0879 ₇₀
										196.0588 ₆₅
										107.0486 ₁₀₀
N12	Oxidative <i>O</i> -demethylation	C ₁₇ H ₂₀ N ₂ O ₅	333.1445	0.5	14.96	68'435	-0.7	15.02	6'454	121.0639 ₁₀₀
										93.0686 ₈
										91.0531 ₂₈
N13	Oxidative <i>O</i> -demethylation	C ₁₇ H ₂₀ N ₂ O ₅	333.1445	0.2	13.50	201'931	0.3	13.52	1'679	121.0646 ₁₀₀
										93.0698 ₆
										91.0532 ₂₅
N14	Oxidative <i>O</i> -demethylation	C ₁₇ H ₂₀ N ₂ O ₅	333.1445	0.9	13.84	230'815	-0.1	13.87	32'874	227.1034 ₆₂
										210.0763 ₇₅
										107.0489 ₁₀₀
25N-NBOMe		C₁₈H₂₂N₂O₅	347.1601	1	15.73	3'773'154	0.2	15.67	13'214'247	121.0642₁₀₀
										93.0609₁₅
										91.0534₃₀
N15	Oxidative <i>O</i> -demethylation, Hydroxylation	C ₁₇ H ₂₀ N ₂ O ₆	349.1394	-0.2	12.44	4'489				227.1043 ₅₃
										210.0757 ₅₀
										123.0438 ₁₀₀
N16	Oxidative <i>O</i> -demethylation, Hydroxylation	C ₁₇ H ₂₀ N ₂ O ₆	349.1394	-0.3	13.38	2'378				272.9789 ₈
										121.0638 ₁₀₀
										91.0540 ₂₅
N17	Oxidative <i>O</i> -demethylation, Hydroxylation	C ₁₇ H ₂₀ N ₂ O ₆	349.1394	-0.6	11.60	2'615				272.9863 ₈
										137.0592 ₁₀₀
										107.0487 ₂₁
N18	Oxidative <i>O</i> -demethylation, Hydroxylation	C ₁₇ H ₂₀ N ₂ O ₆	349.1394	0.4	11.35	29'809				227.1021 ₆₀
										210.0762 ₆₇
										123.0434 ₁₀₀
N19	<i>N</i> -Acetylation of Primary Aromatic Amine	C ₂₀ H ₂₆ N ₂ O ₄	359.1965	0.6	12.92	4'080				222.1125 ₄₀
										180.0999 ₂₃
										121.0636 ₁₀₀
N20	Oxidation of	C ₁₈ H ₂₀ N ₂ O ₆	361.1394	0.5	13.30	3'800				239.0675 ₅

Secondary Alcohol										
N21	<i>N</i> -oxide formation	C ₁₈ H ₂₂ N ₂ O ₆	363.1551	0.3	17.39	5'809	-0.2	17.33	1'762	121.0638 ₁₀₀ 91.0530 ₂₂ 121.0644 ₁₀₀ 93.0683 ₈ 91.0528 ₂₀
N22	Mono-hydroxylation	C ₁₈ H ₂₂ N ₂ O ₆	363.1551	0.2	14.87	8'388	1.4	14.91	431	345.1416 ₅ 121.0639 ₁₀₀ 91.0534 ₂₃
N23	Mono-hydroxylation	C ₁₈ H ₂₂ N ₂ O ₆	363.1551	0.2	13.47	95'806	0.9	13.50	3'654	137.0595 ₈₅ 109.0644 ₁₀₀ 91.0532 ₁₂
N24	Mono-hydroxylation	C ₁₈ H ₂₂ N ₂ O ₆	363.1551	0	13.68	283'892	-0.2	13.71	1'878	137.0606 ₁₀₀ 109.0673 ₃₀ 107.0584 ₂₅





Figure 1: Extracted ion chromatogram of 25D-NBOMe and its metabolites after pHLM incubation with 25D-NBOMe (A). Extracted ion chromatogram of 25D-NBOMe and its metabolites after fungi *C. elegans* incubation with 25D-NBOMe (B).

ACCEPTED





Figure 2 Extracted ion chromatogram of 25-NBOMe and its metabolites after pHLM (2A) and fungi *C. elegans* (2C) incubation with 25E-NBOMe.

Accel





Figure 3 Extracted ion chromatogram of 25N-NBOMe and its metabolites after pHLM (3A) and fungi *C. elegans* (3B) incubation with 25N-NBOMe. For both pHLM and fungi *C. elegans* an N-oxide metabolite (N21) eluted after the parent compound.

Accepted




Figure 4 Proposed biotransformation pathway of 25D-NBOMe. Metabolites labelled with (F) were found in both pHLM and fungi *C. elegans* samples. For structures in brackets the exact site of biotransformation could not be determined.

Accepted




Figure 5 Suggested biotransformation pathway of 25E-NBOMe. Metabolites labelled with (F) were found in both pHLM and fungi *C. elegans* samples. In brackets: exact site of biotransformation could not be determined

Accepted




Figure 6 Proposed biotransformation pathway of 25N-NBOMe. Metabolites labelled with (F) were identified in pHLM and fungi *C. elegans*. In brackets: exact site of biotransformation could not be determined.

Accepted






Figure 7 Nomenclature used for the identification of metabolites.


D14: C₁₈H₂₃NO₄ [M+H]⁺ *m/z* 318.1700; RT 12.261 min




D22: C₁₉H₂₅NO₄ [M+H]⁺ *m/z* 332.1856; RT 12.439 min



D27: C₁₉H₂₅NO₄ [M+H]⁺ *m/z* 332.1856; RT 18.248 min




D30: C₁₉H₂₅NO₅ [M+H]⁺ *m/z* 348.1806; RT 10.709 min




AC


E9: C₁₉H₂₅NO₃ [M+H]⁺ *m/z* 316.1907; RT 17.500 min




E14: C₁₉H₂₅NO₄ [M+H]⁺ *m/z* 332.1856; 12.340 min



E15: C₁₉H₂₅NO₄ [M+H]⁺ *m/z* 332.1856; 14.142 min



E22: C₂₀H₂₇NO₄ [M+H]⁺ *m/z* 346.2013; RT 13.744 min



A





Figure 8 Representative product ion spectra of 25D-NBOMe (A, B, C, D), 25E-NBOMe (E, F, G, H) and 25N-NBOMe (I, J, K) metabolites after incubation in pHLM and fungi *C. elegans*. Fragmentation was selected for the ten most abundant precursor ions with CE of 35 eV with a CES of ± 15 eV.

***In vitro* phase I metabolism of three phenethylamines 25D-NBOMe, 25E-NBOMe and 25N-NBOMe using microsomal and microbial models**

Katharina Elisabeth Grafinger, Katja Stahl, Andreas Wilke, Stefan König, Wolfgang Weinmann

pHLM:



- Results of the microsomal pHLM and microbial fungi *C. elegans* experiments, analysed with LC-HR-MS/MS identified 36 25D-NBOMe, 26 25E-NBOMe and 24 25N-NBOMe phase I metabolites. N-oxides and hydroxylamine metabolites were reported for 25X-NBOMes for the first time and unique 25N-NBOMe metabolites identified.

Accepted